Available technologies
Enhanced antibiotics for MDR/XDR gram-negative infections
Team
Life Science
Industry
Healthcare
Sector
Therapeutic Programs
UQ researchers have identified a novel class of octapeptin derivatives with improved activity against multiple gram-negative bacteria strains that cannot be treated by any other tested antibiotic.
Winning pitch
Biocurate Award: Best Translational Research
‘Octapeptin X – a novel antibiotic for Gram-negative bacterial infections’ claimed the 2020 BioCurate Award for Best Translational Research Pitch at the recent AusBiotech Early Stage Investment Forum.
Congratulations to Dr Tamsin Terry for presenting the winning pitch from a field of 13 early stage technologies in the area of human therapeutics, medical devices and diagnostics, digital health and enabling technologies.
Key features
- Novel lipopeptide antibiotics that target multi and extensively drug resistant (MDR, XDR) gram negative bacteria
- Greater efficacy with significantly reduced nephrotoxicity compared to current standard of care
- Targets the most critical pathogens identified by WHO: Carbapenem-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacteriaceae
- Potential for these novel lipopeptides as a “resistance breaker” to synergise with existing antibiotics to potentiate their activity against MDR/XDR bacteria.
